Drug Trial Radar · NCT06340048
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
Last checked: Nov 20, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Sep 5, 2023
Primary completion
Nov 10, 2026
Study completion May 10, 2027
Sponsor
- Lead sponsor
- HELP Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- TEDA International Cardiovascular Hospital
- First posted
- Apr 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the feasibility, safety and efficacy of intramyocardial injection of human induce pluripotent stem cell-derived cardiomyocytes (HiCM-188) during coronary artery bypass grafting (CABG) surgery in patients with severe chronic ischemic heart failure.
Conditions
- Heart Failure
Interventions
HiCM-188 therapyDrug
Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of major Serious Adverse Events (SAE)Time frame: Within the first month after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TEDA International Cardiovascular Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.